



HAL
open science

Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

Daphne Hompes, Theo Ruers

► **To cite this version:**

Daphne Hompes, Theo Ruers. Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. *EJSO - European Journal of Surgical Oncology*, 2011, 37 (9), pp.737. 10.1016/j.ejso.2011.06.004 . hal-00723460

HAL Id: hal-00723460

<https://hal.science/hal-00723460>

Submitted on 10 Aug 2012


HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

Authors: Daphne Hompes, MD Theo Ruers, MD, PhD



PII: S0748-7983(11)00319-2

DOI: [10.1016/j.ejso.2011.06.004](https://doi.org/10.1016/j.ejso.2011.06.004)

Reference: YEJSO 3178

To appear in: *European Journal of Surgical Oncology*

Accepted Date: 13 June 2011

Please cite this article as: Hompes D, Ruers T. Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer, *European Journal of Surgical Oncology* (2011), doi: 10.1016/j.ejso.2011.06.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title page:

Review:

**Incidence and clinical significance of Bevacizumab-related
non-surgical and surgical serious adverse events
in metastatic colorectal cancer.**

Authors:

1. Daphne Hompes, MD,

Department of Surgery, Antoni van Leeuwenhoek Hospital – The Netherlands
Cancer Institute, Amsterdam, The Netherlands

e-mail: d.hompes@nki.nl

2. Theo Ruers, MD, PhD,

Department of Surgery, Antoni van Leeuwenhoek Hospital – The Netherlands
Cancer Institute, Amsterdam, The Netherlands

e-mail: t.reurs@nki.nl

Corresponding author:

D.Hompes, MD

Antoni van Leeuwenhoek Hospital – The Netherlands Cancer Institute,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Tel.: 0031-20-512 2565 Fax: 0031-20-512 2549

e-mail: d.hompes@nki.nl or daphnehompes@yahoo.com

Category of submission: Review

The paper is not based on a previous communication to a society or meeting.

Abstract:

Objective and Background: This review describes the extent, frequency and clinical importance of Bevacizumab(BV)-related serious adverse events (SAE) after surgery, during or after chemotherapy with BV in patients with metastatic colorectal cancer (mCRC).

Methods: Detailed PubMed search in november 2009.

Results: Addition of BV to first- or second-line chemotherapy in patients with mCRC results in a statistically significant benefit in OS, PFS and RR.

Addition of BV to chemotherapy causes no clinically relevant aggravation of SAE and seems safe with the primary tumor still in situ. The risk of emergency surgery due to BV-related SAE is estimated 2.0%.

SAE rate is low if a time to surgery of 5-6 weeks is respected. The majority of SAE are wound healing complications. Bleeding and GI perforation occur infrequently, even following major surgery after BV-treatment. Major surgery during the course of BV-treatment results in an SAE rate of 1.3-2.7%. Postoperatively, a period of minimally 28 days should be respected before starting BV.

Conclusion: Reported rates of BV-related SAE in relationship to surgery are low.

Keywords:

Metastatic colorectal cancer, bevacizumab, complications, surgical, non-surgical

Abbreviations:

Vascular endothelial growth factor (VEGF), Bevacizumab (BV), VEGF receptor (VEGFR), adverse events (AE), serious adverse events (SAE), arterial hypertension (AHT), gastrointestinal (GI), wound healing complications (WHC), arterial thromboembolic events (ATE), venous thromboembolic events (VTE), time to surgery (TTS), colorectal cancer (CRC), metastatic CRC (mCRC), overall survival (OS), progression-free survival (PFS), response rate (RR), randomized controlled trial (RCT), 5-fluorouracil/leucovorin (5FU/LV), Memorial Sloan Kettering Cancer Center (MSKCC)

Review:**Incidence and clinical significance of Bevacizumab-related
non-surgical and surgical serious adverse events
in metastatic colorectal cancer.**

Hompes D., Ruers T.

The Netherlands Cancer Institute, Amsterdam, The Netherlands

Introduction

Angiogenesis is the formation of new blood vessels by remodeling and expansion of primary vessels, which is crucial for tumor growth beyond 1-2mm and for metastasis. Tumoral angiogenesis is the result of complex molecular mechanisms and appears to be highly related to oxygen deprivation. Vascular endothelial growth factor (VEGF) is a glycoprotein that induces neovascularization and has an increased expression in tumor cells. Angiogenesis of tumor vasculature is fenestrated, chaotic and abnormal, which creates abnormal blood vessels and impairs effective delivery of chemotherapeutic agents to the targeted cancer cells¹⁻³.

Bevacizumab (BV) is a humanized monoclonal antibody that neutralizes the ability of all active VEGF-isoforms to bind to the VEGF receptor (VEGFR) on the surface of endothelial cells. It has 2 potentially cytostatic effects: prevention of neovascularization and normalization of immature and abnormal blood vessels^{1,4,5}. This is assumed to retard the shedding of metastatic cells in the circulation and improve the delivery of therapeutic agents in tumors⁶. Pharmacodynamic data on BV suggest that combination with cytotoxic chemotherapy enhances its anti-tumor activity¹.

On the other hand, VEGF has critical role in wound healing, liver regeneration and endothelial integrity. Therefore, one can expect an anti-VEGF agent, such as BV, to cause mechanism-related serious adverse events (SAE) due to the reduction of VEGF availability⁵. The most frequently described side effects are arterial hypertension (AHT), gastrointestinal (GI) perforations, wound healing complications

(WHC), serious bleeding, arterial and venous thromboembolic events (ATE and VTE), renal toxicity and influences on liver parenchyma^{5,7-13}. Pharmacokinetic studies show that BV has a half-life of 20 days [range 11-50 days]. Consequently, BV-effects may persist despite discontinuation before surgery, but the time for dissipation of BV's pharmacologic effects after the last dose has not been established. A dose of 5mg/kg every 2 weeks is accepted to be the most effective dose of BV. Waiting for two half-lives (i.e. ± 6 weeks) would leave the equivalence of a dose of 1.25mg/kg in the circulation. This is far above the BV level that removes free VEGF from the circulation¹⁴⁻¹⁶. Hence, the time to surgery (TTS) that should be respected after discontinuation of BV has not been clearly defined yet. Recommendations vary from a TTS of 5-6 weeks^{1,7,17} to a more careful 6-8 week interval¹⁶. For postoperative initiation of BV a period of 28 days after surgery and a fully healed surgical incision are recommended, because of possible impairment of wound healing under BV¹⁶⁻¹⁸.

The aim of this paper is to review currently available literature, describing the actual extent, frequency and clinical importance of BV-related SAE after minor and major surgery, during or after systemic chemotherapy with BV, in patients with metastatic colorectal cancer (mCRC).

Methods

A detailed PubMed search was performed in september 2010, using the following keywords: angiogenesis, angiogenesis-inhibitors, VEGF, anti-VEGF, bevacizumab, Avastin, surgery, complications, adverse events, metastatic colorectal cancer, wound healing, bleeding, hemorrhage, gastrointestinal perforation, thromboembolism. The search was limited to articles published in the English language and the eldest publication extracted dates from February 2001.

Results

Overall Survival, Progression-Free Survival and Response Rate [Table 1]

Table 1 gives an overview of data on overall survival (OS), progression-free survival (PFS) and response rate (RR) reported by 7 randomized controlled trials

(RCTs)^{19-25,31}, 4 prospective^{8,26-28} and 3 retrospective studies^{11,29,30}. A recent Cochrane Database systematic review by Wagner et al., including 5 randomized trials (>3000 patients)^{19,22,23,25,31}, concluded BV prolongs both PFS and OS in patients with mCRC. The effect on PFS shows significant heterogeneity, which is probably attributable to differences in the treatment effect of BV in combinations with different “chemotherapy backbones” (i.e. different combinations of 5FU/LV, oxaliplatin, irinotecan). Furthermore, an absolute increase in tumor response of approximately 3% was found in favor of the patients treated with BV².

Non-surgical BV-related Serious Adverse Events

Prospective data (observational trials and RCTs)

Table 2 summarizes the serious adverse events (SAE, i.e. grade 3-5 adverse events) assumed to be related to BV-based chemotherapy, as reported by 6 RCT, 2 prospective observational trials and one pooled analysis of 2 RCT¹⁹⁻²⁸. The authors agree that most BV-related adverse events (AE) are mild to moderate in severity and manageable using standard therapies. The First BEAT study reported grade 5 toxicity in 2% of patients, including hemorrhage (<0.5%), cardiac disorders (<0.5%), respiratory disorders (<0.5%), venous embolism (1%) and GI perforation (0.4%). An intention-to-treat-based analysis showed a 3% 60-day mortality²⁷. The review by Wagner et al. showed no significant differences for treatment-related deaths and 60-day mortality with or without BV². However, the number of treatment interruptions due to AE was significantly higher under chemotherapy with BV than without (21% versus 15%)². The majority of trials attributed the most significant increase in toxicity to a significantly higher incidence of arterial hypertension (AHT) [Table 2]. Many trials also reported an increase in ATE [Table 2]. According to the analysis by Wagner et al. the increase in grade 3-4 AHT and ATE should be rated as statistically significant². Bleeding as a SAE was reported from 0 to 5% in patients under BV-based treatment [Table 2]. In the ECOG study E3200 the incidence of hemorrhage was statistically higher for patients under second-line chemotherapy with BV ($p=0.011$)²². This was confirmed by the review of Wagner et al., whereas a non-significant increased incidence of bleeding was found under BV in first-line chemotherapy². GI perforation was defined by Kabbinavar et al. as all events reported as GI abscess, perforation

and fistula of any grade unrelated to surgery²⁰. A rate of “spontaneous” GI perforations under BV of up to 3% was recorded [Table 2]. An extensive meta-analysis by Hapani et al. reported an incidence of GI perforation under BV treatment of <1%, resulting in a mortality of 22%³². Patients under BV-treatment had a significantly increased risk of GI perforation, with a positive correlation with higher doses of BV (5mg/kg versus 2.5mg/kg per week) and colorectal cancer (CRC)³². In general, most authors agreed the addition of BV to chemotherapy caused no clinically relevant aggravation of chemotherapy-related SAE. Patients aged ≥ 65 years didn't appear to have greater risk with BV-treatment than younger patients^{20,28}, except for a relatively higher proportion of ATE in patients ≥ 75 years^{2,28}. Furthermore, despite more ECOG PS score >1 and more comorbidities in the BRiTE study, the SAE rate was not substantially different from other BV-treated RCT cohorts²⁸.

Risk for emergency surgery under BV-treatment?

Few papers specify the risk for emergency surgery that is due to SAE in patients under BV-treatment. Poultides et al. retrospectively described that out of 233 patients who received up-front triple drug chemotherapy (with oxaliplatin or irinotecan) with or without BV 16 patients (7%) underwent emergent surgery under chemotherapy: 5 resections for perforations and 3 resections plus 8 diversions for primary tumor obstruction³⁰. Only 2 of the 5 tumor perforations occurred under BV-treatment. For the obstructive events the number of patients under BV was not clearly specified. No intractable bleedings, necessitating surgical intervention, were reported. Two patients with primary tumor complications (<1%) died within 30 days of surgery. The authors didn't specify whether these patients were on BV-treatment, but they concluded that the risk of emergent intervention was not associated with the use of BV³⁰. Of 529 patients under BV-based treatment in the ECOG study E3200 only 1 developed a grade 4 bleeding that required a hemostatic intervention and 6 events of bowel perforation were reported, 2 of which needed surgery and 2 cases were fatal²². In a multicenter trial of Kabbavar et al. 2 of the 104 patients under BV-based treatment developed a bowel perforation (each associated with a colonic diverticulum). One patient died due to this complication. Nevertheless, SAE leading to death or study discontinuation were found to be similar with or without BV²³, which concurs with the analysis of Wagner et al².

Risks of BV-treatment if the primary tumor is still in situ?

In case of asymptomatic synchronous stage IV CRC, the rationale for immediate resection of the primary tumor would be the prevention of primary-related AE that might make urgent surgery under chemotherapy necessary, thus possibly increasing mortality. On the other hand, immediate resection of an asymptomatic primary might cause an important delay or even exclude some patients from chemotherapy³⁰. Few trials report specifically on the incidence of major complications related to the primary tumor in synchronous stage IV CRC under BV-based therapy. The First BEAT study reported a GI perforation in 8 of 223 patients (4%) with unresected primary tumors: only 3 of them occurred at the primary tumor site²⁷. In the BRiTE study GI perforation rate was 3% in patients with an intact primary versus almost 2% in case of a resected primary tumor²⁸. Multivariate analysis rated this as an independent risk factor for GI perforation, but event numbers were low: only 9 out of 305 patients (3%) with an unresected primary tumor developed a GI perforation. Whether these perforations occurred at the primary tumor site, was not specified. Based on a literature search, Poultides et al. concluded that virtually all BV-related perforations were observed in the first 3 months of treatment (mostly within the first month) and occurred throughout the entire GI tract, hardly ever involving the site of the primary tumor^{22,25,30}.

BV-related complications after surgery***RCT data [Table 3]***

The pooled analysis by Scappaticci et al.³³ includes 1132 patients, who underwent 5FU/leucovorin- or Folfiri-based chemotherapy with or without BV in a phase II²³ and phase III RCT²⁵. This population was analyzed in two groups: In group 1 chemotherapy (with or without BV) was started 28-60 days after surgery and complication rates were similarly low in both groups (around 1%). In group 2 patients underwent major or emergent surgery during chemotherapy with or without BV. The higher number of surgical procedures in BV-treated patients was not explained, but apparently there were more elective, non-cancer related procedures in this group. The difference in SAE incidence with or without BV (13% versus 3%) didn't reach statistical significance. Nevertheless, it might have clinical relevance, so careful monitoring of patients who need to undergo major surgery during BV-based

chemotherapy is recommended. The “major” surgical procedures in the pooled analysis by Scappaticci et al. are listed in Table 5B. The small number of events in this analysis made it impossible to draw definite conclusions on the appropriate timing of surgery following the last BV dose as well as the influence of comorbidity (e.g. diabetes, obesity, smoking) on healing processes³³. The NSABP C-08 trial (National Surgical Adjuvant Breast and Bowel Project) compared Folfox with or without BV in the adjuvant setting for stage II and III CRC. In this study BV increased the risk of wound healing complications (WHC), even if it was initiated 6 weeks from the time of surgery. Furthermore, it was suggested that extended use of BV can increase the long-term risk of WHC for up to 6 months after its cessation^{18,34}.

Prospective observational data [Table 4]

In the First BEAT study almost 12% of patients underwent surgery with curative intent “during trial participation”, of whom 64% (145 patients) underwent hepatectomy [Table 5A]. Bleeding was reported as an SAE in almost 3% and WHC in 2.0%²⁷. In the BRiTE study almost 27% patients underwent surgery within 90 days of the last BV dose, of whom 30% (175 patients) underwent major abdominal surgery and 17% (88 patients) underwent hepatectomy. The incidence of serious WHC was 4.4%. The absolute number of severe WHC appeared higher after major than after minor surgery: 6% of abdominal procedures and 6% of hepatectomies developed severe WHC versus 3% for minor surgical procedures²⁸ [Table 5B]. A subanalysis of the time to surgery (TTS) was performed [Table 5B], but no multivariate analysis was performed for WHC because event numbers were low. Concerning severe bleeding, a multivariate analysis couldn't identify significant risk factors, not even antiplatelet therapy or anticoagulation²⁸. This concurs with a trial of Saltz et al., who found bleeding events to be similar for BV-based chemotherapy with and without concurrent anticoagulation therapy¹⁹. Unfortunately, the BRiTE study and the First BEAT trial didn't clearly specify the number of severe bleeding events that occurred postoperatively. Gruenberger et al. prospectively reported on 52 liver resections 5 weeks after BV³⁵: Thirty-six percent of patients underwent a major hepatectomy (i.e. resection of ≥ 3 liver segments) [Table 5A]. Eleven postoperative SAE were recorded: 1 bowel perforation (for which reoperation was needed), 1 anastomotic leak, 1 wound hematoma, 1 wound infection, 3 cases of sepsis and 1 bile leak. There were no severe bleeding events. Twenty-one percent of patients underwent

synchronous resection of liver and primary tumor [Table 5A], resulting in similar peri- and postoperative complication rates as in patients undergoing only hepatectomy. Concerning liver function and regeneration, Gruenberger et al. reported normal findings in 51 patients (98%)²⁶. This concurs with observations from MD Anderson¹¹ and a retrospective analysis by Klinger et al⁸, which suggests a reduced incidence and severity of oxaliplatin-related sinusoidal dilatation in patients under chemotherapy with BV. Finally, 2 phase I studies by Willett et al. included a very small number of patients who all underwent major surgery after BV-based chemotherapy. Reported complications were low^{6,36} [Table 5B].

Retrospective data

Zawacki et al. performed the only study focusing purely on minor surgery under BV-based chemotherapy [Table 5C]. They analyzed WHC as a SAE under BV-treatment with variable doses before or after placement of a venous access port. All 6 dehiscences occurred under BV-treatment. Despite the very small number of events statistical analysis was performed and the authors concluded that patients receiving BV within 10 days of port placement had a higher incidence of wound dehiscence³⁷. A study from MD Anderson focused on hepatic surgery after chemotherapy with or without BV: 30% of patients underwent major hepatectomy³⁸ [Table 5A]. Median time between discontinuation of BV and surgery was 58 days [range 31-117]. No significant association was found between use of BV and postoperative complication rate (49% with vs. 43% without BV). The time interval from discontinuation of BV to surgery was not associated with an increased likelihood of developing complications³⁸. Reddy et al. analyzed morbidity of hepatectomy after irinotecan- or oxaliplatin-based chemotherapy with or without BV: 24% of patients underwent major hepatectomy and in 16% of patients synchronous extrahepatic procedures were performed³⁹ [Table 5A]. The differences in complications after chemotherapy with or without BV were all rated statistically insignificant. An analysis for TTS (\leq or >8 weeks) showed no significant differences for overall, severe and hepatic complications³⁹. D'Angelica et al. studied the influence of BV-based chemotherapy within 12 weeks from hepatectomy: 27% of patients underwent major hepatectomy⁴⁰ [Table 5A]. Only 2 SAE (grade 3) were reported under BV: 1 subphrenic abscess and 1 groin abscess. Because of the heterogenous timing of BV administration (before, after or before and after surgery) and the low complication rate definitive conclusions

are difficult, but the perioperative complication profile was within the limits expected in any group of patients undergoing hepatectomy⁴⁰. Finally, Bose et al. suggested that, although a period of 28 days is recommended for postoperative initiation of BV, the time point for the start of BV should be individualized in case of comorbidity (e.g. diabetes, peripheral vascular disease) or wound-healing issues, thus allowing more time for wound healing¹⁶.

Discussion

The BV-related SAE reported in literature are mild to moderate in severity and manageable using standard therapies. Furthermore, the incidence of SAE under BV-based chemotherapy is low: even very large, multicenter prospective and randomized controlled trials reported only very small numbers of SAE. In most trials the incidence of hemorrhage (2.0-3.0%), GI perforation (<1.0-2.0%) and ATE (1.0-2.0%) was higher under BV-based treatment, but overall the absolute number of patients affected remained very low. Also, BV-related grade 5 toxicity was rare. Thus, most authors agreed the addition of BV to chemotherapy caused no clinically relevant aggravation of chemotherapy-related SAE. Only few trials report specifically on the incidence of major complications related to the primary tumor in synchronous stage IV CRC under BV-based therapy. With the primary tumor still in situ during chemotherapy, BV-related GI perforations occur in about 3% of patients, but virtually all of these were observed in the first 3 months of treatment and occurred throughout the entire GI tract, hardly ever involving the primary tumor site. Thus, leaving the primary tumor in place during BV-treatment appears safe. Finally, the risk emergency surgery might be needed due to BV-related SAE, such as bleeding or perforation, is very low (estimated 2.0%).

The relation between postoperative SAE and BV-based chemotherapy can be divided in 3 groups: First, for patients undergoing surgery after BV discontinuation trials showed very low rates of SAE if a TTS of 5-6 weeks is respected. The majority of SAE reported are WHC. Bleeding and GI perforation occur infrequently. In most of these trials 30-40% of patients undergo major surgery, which suggests the low rate of SAE reported should be reliable. For minor surgery, WHC are the main issue, but rates are low if BV is discontinued within a 10 day period around the procedure.

Second, patients undergoing major or emergency surgery during BV-treatment seemed at higher risk (SAE 1.3-2.7% vs. 0.0%), but this was rated statistically insignificant. The reported numbers of SAE remained relatively small in this setting, but they could still be clinically relevant. Thus, close monitoring of patients undergoing surgery under BV is advisable. Third, for the start of BV-treatment after major surgery few data are available. Small rates of SAE were found, especially if a period of minimally 28 days after surgery is respected before starting BV. However, in case of comorbidity or wound-healing issues after surgery, the time point for starting BV should be individualized to allow more time for wound healing.

Conclusion

This review shows that even trials consisting of large patient populations report small numbers of SAE of BV-related SAE in relationship to surgery. This has 2 consequences: Small numbers of events make statistical analysis and definitive conclusions difficult, if not impossible. On the other hand, the fact that even large populations show low absolute numbers of BV-related SAE in any of the settings examined above, suggest that BV-based treatment causes few clinically significant problems even when surgical procedures are involved.

Conflict of interest statement:

The authors have no disclosures to make concerning financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.

Sources of funding: no sources of funding for research and/or publication were granted for this paper.

References:

1. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. *Clin Therap* 2006; 28: 1779-1802.
2. Wagner A, Arnold D, Grothey A. Anti-angiogenic therapy for metastatic colorectal cancer. *Cochrane Database Syst Rev* 2009; 8(3): CD005392.
3. McDonald D, Baluk P. Significance of blood vessel leakiness in cancer. *Cancer Res* 2002; 62: 5381-5385.

4. Cao Y, Zhong W, Sun Y. Improvement of angiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. *Semin Cancer Biol* 2009 may 27 [Epub ahead of print]
5. Los M, Roodhart J, Voest E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. *The Oncologist* 2007; 12: 443-450.
6. Willett CG, Boucher Y, di Tomaso E. Direct evidence that the VEGF-specific antibody bevacizumab has antivasular effects in human rectal cancer. *Nat Med* 2004; 10: 145-147.
7. Nordlinger B, Van Cutsem E, Gruenberger T. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. *Ann Oncol* 2009; 20: 985-992.
8. Klinger M, Eipeldauer S, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant xelox/folfox therapy of colorectal cancer liver metastases. *Eur J Surg Oncol* 2009; 35: 515-520.
9. Schiff D, Wen P, van den Brent M. Neurological adverse effects caused by cytotoxic and targeted therapies. *Nat Rev Clin Oncol* 2009; 6: 596-603.
10. Kelly R, Billemont B, Rixe O. Renal toxicity of targeted therapies. *Target Oncol* 2009; 4: 121-33.
11. Ribero D, Wang H, Vauthey J. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. *Cancer* 2007; 110: 2761-2767.
12. Fakih M, Lombardo J. Bevacizumab-induced nasal septum perforation. *The Oncologist* 2006; 11: 85-86.
13. Nalluri S, Chu D, Keresztes R. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. *JAMA* 2008; 300: 2277-2285.
14. Ellis L, Curley S, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. *J Clin Oncol* 2005; 23: 4853-4855.
15. Gordon M, Margolin K, Talpaz M. Phase I safety and pharmacokinetic study of recombinant human anti-Vascular Endothelial Growth Factor in patients with advanced cancer. *J Clin Oncol* 2001; 19: 843-850.
16. Bose D, Meric-Bernstam F, Hofstetter W. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. *Lancet Oncol* 2010; 11: 373-382.

17. Infobrochure Roche: Avastin.
18. Allegra C, Yothers G, O'Connell M. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. *J Clin Oncol* 2009; 27: 3385-3390.
19. Saltz L, Clarke S, Diaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008; 26: 2013-2019.
20. Kabbinavar F, Hurwitz H, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. *J Clin Oncol* 2009; 27: 199-205.
21. Hochster H, Hart L, Hedrick E. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. *J Clin Oncol* 2008; 26: 3523-3529.
22. Giantonio B, Catalano P, Meropol N. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 2007; 25: 1539-1544.
23. Kabbinavar F, Schulz J, Novotny W. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. *J Clin Oncol* 2005; 23: 3697-3705.
24. Kabbinavar F, Hambleton J, Hurwitz H. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol* 2005; 23: 3706-3712.
25. Hurwitz H, Fehrenbacher L, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; 350: 2335-2342.
26. Gruenberger B, Tamandl D, Gruenberger T. Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. *J Clin Oncol* 2008; 26: 1830-1835.
27. Van Cutsem E, Rivera F, Cunningham D. Safety and efficacy of first-line bevacizumab with folfox, xelox, folfiri and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Ann Oncol* 2009; 20: 1842-1847.
28. Kozloff M, Yood M, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. *The Oncologist* 2009; 14: 862-870.

29. Blazer D, Kishi Y, Vauthey N. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. *J Clin Oncol* 2008; 25: 5344-5351.
30. Poultsides G, Servais E, Saltz L. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving chemotherapy without surgery as initial treatment. *J Clin Oncol* 2009; 27: 3379-3384.
31. Kabbinnavar F, Hurwitz H, Fehrenbacher L. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with 5FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol* 2003; 21: 60-65.
32. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. *Lancet Oncol* 2009; 10: 559-568.
33. Scappaticci F, Fehrenbacher L, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. *J Surg Oncol* 2005; 91: 173-180.
34. Wolmark N, Yothers G, O'Connell M. A phase III trial comparing mFolfox6 to mFolfox plus bevacizumab in stage II and III carcinoma of the colon: results of NSABP protocol C-08. *Proc Am Soc Clin Oncol* 2009; 27: abstr LBA4.
35. Gruenberger T, Gruenberger B, Scheithauer W. Neoadjuvant therapy with bevacizumab. *J Clin Oncol* 2006; 24: 2592-2593.
36. Willett CG, Boucher Y, Duda D. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. *J Clin Oncol* 2005; 23: 8136-8139.
37. Zawacki W, Walker G, DeVasher E. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. *J Vasc Interv Radiol* 2009; 20: 624-627.
38. Kesmodel S, Ellis L, Lin E. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. *J Clin Oncol* 2008; 26: 5254-5260.
39. Reddy S, Morse M, Hurwitz H. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. *J Am Coll Surg* 2008; 206: 96-106.
40. D'Angelica M, Kornprat P, Saltz L. Lack of evidence for increased morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. *Ann Surg Oncol* 2007; 14: 759-765.

Table 1: Therapy with BV: OS / PFS / RR / CR

	Ref.	Author Trial Journal	N +BV / total	Regimen	OS (m)	PFS (m)	ORR (%)	Complete response on pathology (%)
RCTs	[19]	Saltz <i>Amended NO16966 trial</i> JCO 2008	699/1400	Folfox / Capox +BV	21.3	9.4	47.0	-
				vs	vs	vs		
				Folfox / Capox -BV	19.9	8.0	49.0	-
					(p=0.077)	(p<0.0023)	(p=0.31)	
	[21]	Hochster <i>Amended TREE study</i> JCO 2008	213/360	ivFolfox / bolusFolfox / Capox +BV	23.7	9.9 / 8.3 / 10.3	45.7	-
				vs	vs	vs		
				ivFolfox / bolusFolfox / Capox -BV	18.2	8.7 / 6.9 / 5.9	29.3	-
	[22]	Giantonio <i>ECOG study E3200</i> JCO 2007	529/820	Folfox +BV	12.9	7.3	22.7	-
				vs	vs	vs		
				Folfox -BV	10.8	4.7	8.6	-
			vs	vs	vs			
			BV alone	10.2	2.7	3.3	-	
				(p=0.0011)	(p<0.0001)	(p<0.0001)		
[23]	Kabbinavar* JCO 2005	104/209	5FU/LV +BV	16.6	9.2	26.0	-	
			vs	vs	vs			
			5FU/LV -BV	12.9	5.5	15.2	-	
				(p=0.16)	(p=0.0002)	(p=0.055)		
[24]	Kabbinavar JCO 2005	249/490	IFL +BV	17.9	8.7	34.1	-	
			vs	vs	vs			
			IFL -BV	14.6	5.55	24.5	-	
				(p=0.0081)	(p=0.0001)	(p=0.019)		
[25]	Hurwitz** N Engl J Med 2004	402/813	IFL +BV	20.3	10.6	44.8	-	
			vs	vs	vs			
			IFL -BV	15.6	6.2	34.8	-	
				(p<0.001)	(p<0.001)	(p=0.220)		
[20]	Kabbinavar JCO 2009	218/439	5FU/LV or IFL +BV	19.3	9.2	34.4	-	
			vs	vs	vs			
		Patients ≥ 65years (pooled analysis ***)	5FU/LV or IFL -BV	14.3	6.2	29.0	-	
				(p=0.006)	(p<0.0001)	(p=0.220)		
Prospective trials	[27]	Van Cutsem <i>First BEAT study</i> Ann Oncol 2009	1914/1914	5FU-based chemotherapy +BV	22.7	10.8	-	-
	[28]	Kozloff <i>BRiTE study</i> The Oncologist 2009	1953/1953	“BV-containing therapy” (mainly 5FU-based)	22.9	9.9	-	-
	[26]	Gruenberger EJSO 2009	56/56	Capox +BV	-	-	-	8.9
	[8]	Klinger EJSO 2009	56/106	Capox +BV	-	-	-	8.9
			vs					
			Capox or Folfox -BV	-	-	-	4.0	
							(p=0.57)	
Retrospective trials	[30]	Poultides JCO 2009	112/233	Irino- or Oxali-based chemo +/-BV	18.0	-	-	14.5
	[11]	Ribero Cancer 2007	62/105 (285 nodules)	5FU/Oxaliplatin +BV	-	-	-	11.3
				vs				
				5FU/Oxaliplatin +BV	-	-	-	11.6
							(p=0.59)	
[29]	Blazer JCO 2008	114/305	Irino- or Oxali-based chemo +BV	-	-	-	9.3	
			vs					
			Irino- or Oxali-based chemo +BV	-	-	-	9.2	

Table 2: RCTs / Prospective trials: non-surgical BV-related SAE

Ref.	Author Trial Journal	N +BV / total	Regimen	Non-surgical SAE (%)								
				Hemorrhage	GI perforation	ATE	VTE	AHT	Diarrhea	Leucopenia / neutropenia	Death (within 60d.)	
RCTs	[19]	Saltz <i>Amended NO16966</i> trial JCO 2008	Folfox / Capox +BV	2.0	<1.0	2.0	8.0	4.0	-	-	2.0	
			vs	vs	vs	vs	vs			vs		
		Folfox / Capox -BV	1.0	2.0	1.0	5.0	1.0	-	-	1.6		
	[21]	Hochster <i>Amended TREE</i> study JCO 2008	ivFolfox / bolusFolfox / Capox +BV	1.4	2.3	-	2.7	3.6	18.6	26.0	1.9	
			vs			vs		vs	vs	vs		
		ivFolfox / bolusFolfox / Capox -BV	0.0	-	-	1.3	-	29.3	28.7	3.4		
	[22]	Giantonio <i>ECOG study E3200</i> JCO 2007	Folfox +BV	3.4	0.6	0.9	3.4	6.2	-	-	5.0	
			vs	vs	vs	vs	vs			vs		
			Folfox -BV	0.4	0.0	0.4	2.5	1.8	-	-	4.0	
			vs	vs	vs	vs	vs			vs		
		BV alone	2.1	0.8	0.4	0.4	7.3	-	-	6.0		
			(p=0.011)		(p=0.62)	(p=0.62)	(p=0.008)					
	[23]	Kabbinavar* JCO 2005	5FU/LV +BV	5.0	2.0	10.0	9.0	16.0	39.0	5.0	5.0	
			vs	vs	vs	vs	vs	vs	vs	vs		
		5FU/LV -BV	3.0	0.0	5.0	11.0	3.0	40.0	14.0	13.5		
	[24]	Kabbinavar JCO 2005	IFL +BV	5.0	1.0	5.0	10.0	16.0	37.0	5.0	-	
			vs	vs	vs	vs	vs	vs	vs	vs		
		IFL -BV	2.0	0.0	3.0	9.0	3.0	34.0	19.0	-		
[25]	Hurwitz** N Engl J Med 2004	IFL +BV	3.1	1.5	19.4		11.0	32.4	37.0	4.9		
		vs	vs	vs		vs	vs	vs	vs			
	IFL -BV	2.5	0.0	16.2		2.3	24.7	31.1	3.0			
				(p=0.26)								
[20]	Kabbinavar JCO 2009	5FU/LV or IFL +BV	4.8	2.9	7.6	14.9	13.8	38.6	30.0	6.7		
		vs	vs	vs	vs	vs	vs	vs	vs			
	5FU/LV or IFL -BV	3.7	0.0	2.8	17.5	1.8	33.2	23.5	8.8			
		Patients ≥ 65years (pooled analysis */**)										
Prospective trials	[27]	Van Cutsem <i>First BEAT study</i> Ann Oncol 2009	1914/1914	5FU-based chemotherapy +BV	3.0	2.0	1.0	-	5.0	4.0	-	3.0
	[28]	Kozloff BRiTE study The Oncologist 2009	1953/1953	“BV-containing therapy” (mainly 5FU-based)	2.2	1.9	2.0	-	22.0	-	-	2.1
	[26]	Gruenberger EJSO 2009	56/56	Capox +BV	0.0	2.0	7.0		3.0	33.0	10.0	0.0

Tables 1 & 2:

p-values are mentioned if available

Abbreviations: ng: not given; p=NS: statistically not significant; N +BV/total = number of patients undergoing surgery during or after BV-based treatment over the total population

Table 3: RCT: post-surgery BV-related SAE

Ref.	Author Journal	N surgery +BV / total	Regimen	Post-surgery SAE (%)									
				GI perforation	Abd. fistula	Anastomotic dehiscence	Intra-abd. bleeding	Other Hemorrhages	Wound Healing	Infection	death		
[33]	Scappaticci J Surg Oncol 2005	305/1132 (pooled analysis **/)**	Group 1: Start BV 28-60d. <u>AFTER</u> surgery	5FU/LV or IFL +BV	0.9	-	-	0.4	-	-	-	-	
				vs									
				5FU/LV or IFL -BV	0.0	-	-	0.5	-	-	-	-	-
			Group 2: Major / emergency surgery <u>DURING</u> BV-treatment	5FU/LV or IFL +BV	2.7	2.7	1.3	1.3	1.3	1.3	2.7	2.7	
				vs									
		5FU/LV or IFL -BV	0.0	0.0	3.4	0.0	0.0	0.0	0.0	3.4			

Table 5: Types of surgery vs postop.complications

Ref.	Author (center) Journal	N surgery +BV / total	Types of surgery	TTS	TpS	Post-surgery SAE (%)								
						Hepatic / biliary complications	GI perforation	Abd. Fistula	Anastomotic dehiscence	Hemorrhage	Wound Healing	Infection	other	Death
A. Liver surgery														
[27]	Van Cutsem <i>First BEAT</i> Ann Oncol 2009	225/1914	Curative hepatectomy	145	"during trial participation"	-	-	-	-	2.7	2.0	-	-	3.0
[38]	Kesmodel JCO 2008	81/125	Extended hepatectomy (≥ 5 segm)	17	58 days range [31-117]	9.1	-	-	1.2	-	2.5	3.7	12.3	1.2
			Hemihepatectomy (3 or 4 segm)	30		vs	vs	vs	vs	vs	vs	vs	vs	vs
			Biseg/segmentectomy	12		9.1	-	-	0.0	-	0.0	0.0	9.1	2.3
			Wedge resection	17										
			RFA only	5										
			RFA in addition to resection	20										
			Extrahepatic procedure	12										
[39]	Reddy J Am Coll Surg 2008	39/96	Extended hepatectomy	11	\leq or $>$ 8 weeks	17.9	2.6	-	-	5.3	10.3	-	-	3.5
			Hemihepatectomy	11		vs	vs	vs	vs	vs	vs	vs	vs	
			Other continuous 3-segmentectomy	1		26.3	5.3	-	-	2.6	7.0	-	-	2.6
			Bisegmentectomy	12		(p=NS)	(p=NS)			(p=NS)	(p=NS)			(p=NS)
			Unisegmentectomy	1										
			Wedge resection	3										
			Synchronous hepatic & extrahepatic procedures:	15										
[26]	Gruenberger JCO 2008	56/56	Liver resection only	41	5w.	2.0	2.0	-	2.0	0.0	4.0	2.0	6.0	0.0
			→ Major hepatectomies (≥ 3 segm): 36%										Sepsis	
			Synchronous primary tumor + liver resection	11										
[40]	D'Angelica Ann Surg Oncol 2007	32/64	Hepatectomy	32	Median 6.9 weeks range [3-15]	0.0	-	-	-	0.0	0.0	0.0	6.25	0.0
			→ Major hepatectomy (≥ 3 segm)	17		Median 7.4 weeks range [5-15]								abscess
			→ in addition to hepatectomy:											
			RFA	1										
			Cryoablation	2										
			Biliary resection + HJS	1										
			Synchronous hepatic + colorectal resection:	9										
B. Other major surgery														
[28]	Kozloff <i>BRiTE</i> The Oncologist 2009	521/1953	Major surgery:		"within 90 days"	-	-	-	-	-	4.4	1.5	-	-
			-abdominal	157										
			-hepatectomy	88										
			Minor surgery:	67										
[33]	Scappaticci J Surg Oncol 2005	305/1132	Bowel surgery	28	Major / emergency surgery during BV	-	2.7	2.7	1.3	2.6	1.3	1.3	-	2.7
			Exploratory laparotomy	8		vs	vs	vs	vs	vs	vs	vs	vs	
			Non-GI surgery	17		-	0.0	0.0	3.4	0.0	0.0	0.0	-	3.4
			Abscess/fistula drainage	7										
			Hepatic metastasectomy	4										
			Other GI	7										
			Unknown	4										
[36]	Willet JCO 2005	5	LAR	4	7-9 weeks	-	20.0	0.0	0.0	0.0	0.0	0.0	20.0	-
			APR	1										
[6]	Willet Nat Med 2004	6	Resection rectal cancer	6	7 weeks	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-
C. Minor surgery														
[37]	Zawacki J Vasc Interv Radiol 2009	189/1082	Venous access port	195	7-44 days	1-44 days	-	-	-	-	3.2	4.2	-	-

Tables 3, 4 & 5:

p-values: mentioned if available

ng: not given; p=NS: statistically not significant; TTS: time to surgery, i.e. the time interval between discontinuation of BV and surgery; TpS: time post surgery, i.e. the time interval between surgery en (re)start of BV; $N_{\text{surgery +BV}} / \text{total}$ = number of patients undergoing surgery during or after BV-based treatment over the total population

ACCEPTED MANUSCRIPT